v3.26.1
Condensed Statements of Changes in Shareholder’S Deficit (Unaudited) - USD ($)
Class A [Member]
Ordinary shares
Class B [Member]
Ordinary shares
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2025 $ 1,000 $ 24,000 $ (47,000) $ (22,000)
Balance (in Shares) at Dec. 31, 2025 6,708,333 [1]      
Issuance of 641,250 Private Placement Units to Sponsor and underwriters at $10.00 per unit 6,413,000 6,413,000
Issuance of 641,250 Private Placement Units to Sponsor and underwriters at $10.00 per unit (in Shares) 641,250      
Estimated fair value of 6,708,333 Public Warrants issued as part of Units sold in the Offering 2,616,000 2,616,000
Allocated value of transaction costs to Public and Private Warrants (151,000) (151,000)
Accretion in value of Class A ordinary shares (8,902,000) (6,359,000) (15,261,000)
Net income 816,000 816,000
Balance at Jun. 30, 2026 $ 1,000 (5,590,000) (5,589,000)
Balance (in Shares) at Jun. 30, 2026 641,250 6,708,333 [1]      
Balance at Mar. 31, 2026 $ 1,000 24,000 (85,000) (60,000)
Balance (in Shares) at Mar. 31, 2026 6,708,333 [1]      
Issuance of 641,250 Private Placement Units to Sponsor and underwriters at $10.00 per unit 6,413,000 6,413,000
Issuance of 641,250 Private Placement Units to Sponsor and underwriters at $10.00 per unit (in Shares) 641,250        
Estimated fair value of 6,708,333 Public Warrants issued as part of Units sold in the Offering 2,616,000 2,616,000
Allocated value of transaction costs to Public and Private Warrants   (151,000) (151,000)
Accretion in value of Class A ordinary shares (8,902,000) (6,359,000) (15,261,000)
Net income 854,000 854,000
Balance at Jun. 30, 2026 $ 1,000 $ (5,590,000) $ (5,589,000)
Balance (in Shares) at Jun. 30, 2026 641,250 6,708,333 [1]      
[1] Includes up to 875,000 Class B ordinary shares, at both December 31, 2025 and March 31, 2026, that were subject to forfeiture if the over-allotment option had not been exercised in full by the underwriters at the closing of the Public Offering on April 1, 2026 (see Note 5).